CAM
TCRT icon

ClariVest Asset Management’s Alaunos Therapeutics TCRT Stock Holding History

ClariVest Asset Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,031
Closed -$390K – 803
2020
Q4 		$390K Sell
1,031
-16
-2% -$6.36K 0.01% 432
2020
Q3 		$396K Buy
1,047
+172
+20% +$76K 0.01% 380
2020
Q2 		$430K Buy
+875
New +$390K 0.01% 426

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

ClariVest Asset Management's TCRT Position: Q1 2021 in Review

ClariVest Asset Management sold out of Alaunos Therapeutics (TCRT) in Q1 2021, closing a stake of 1,031 shares — an estimated $390K sold.

ClariVest Asset Management first reported a position in TCRT in Q2 2020 and held it in 3 quarters. The position peaked at $430K in Q2 2020. 151 funds tracked by Wall St. Rank hold TCRT as of Q1 2021.

  • ClariVest Asset Management reported no remaining Alaunos Therapeutics position as of Q1 2021 after selling out during the quarter.
  • ClariVest Asset Management sold 1,031 Alaunos Therapeutics shares in Q1 2021, an estimated $390K.
  • ClariVest Asset Management first reported a position in Alaunos Therapeutics in Q2 2020 and held it in 3 quarters.
  • ClariVest Asset Management's Alaunos Therapeutics position peaked at $430K in Q2 2020.
  • 151 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2021.

Based on ClariVest Asset Management's 13F filing for Q1 2021, filed 13 May 2021.